Literature DB >> 2144420

[Comparative bioavailability of eicosapentaenoic acid and docasahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteers].

B Beckermann1, M Beneke, I Seitz.   

Abstract

Comparative Bioavailability of Eicosapentaenoic Acid and Docosahexaenoic Acid from Triglycerides, Free Fatty Acids and Ethyl Esters in Volunteers. The bioavailability of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from triglycerides, free fatty acids and ethyl esters was investigated in 8 female volunteers in a randomized triple cross-over trial with baseline control. EPA/DHA was administered in capsules in form of triglycerides (1.68/0.72 g), free fatty acids (1.35/1.065 g) and ethyl esters (1.86/1.27 g). The resulting EPA/DHA plasma levels were determined and evaluated. The mean relative bioavailability of EPA/DHA compared to triglycerides was 186/136% from free fatty acids and 40/48% from ethyl esters. Maximal plasma levels were about 50% higher with free fatty acids and about 50% lower with ethyl esters as compared to triglycerides. The tolerability of the free fatty acids was much worse than that of triglycerides and ethyl esters. The main side effect was eructation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144420

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  17 in total

1.  Omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease: do formulation, dosage & comparator matter?

Authors:  James J DiNicolantonio; Pascal Meier; James H O'Keefe
Journal:  Mo Med       Date:  2013 Nov-Dec

2.  Cholestane as a digestibility marker in the absorption of polyunsaturated fatty acid ethyl esters in Atlantic salmon.

Authors:  S Sigurgisladottir; S P Lall; C C Parrish; R G Ackman
Journal:  Lipids       Date:  1992-06       Impact factor: 1.880

Review 3.  The absorption of fish oils and concentrates.

Authors:  R G Ackman
Journal:  Lipids       Date:  1992-11       Impact factor: 1.880

4.  Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations--a comparative bioavailability study of fish oil vs. krill oil.

Authors:  Jan Philipp Schuchardt; Inga Schneider; Henrike Meyer; Juliane Neubronner; Clemens von Schacky; Andreas Hahn
Journal:  Lipids Health Dis       Date:  2011-08-22       Impact factor: 3.876

5.  Short term effects of different omega-3 fatty acid formulation on lipid metabolism in mice fed high or low fat diet.

Authors:  Xiao Tang; Zhao-Jie Li; Jie Xu; Yong Xue; Jin-Zhang Li; Jing-Feng Wang; Teruyoshi Yanagita; Chang-Hu Xue; Yu-Ming Wang
Journal:  Lipids Health Dis       Date:  2012-07-10       Impact factor: 3.876

Review 6.  A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels.

Authors:  Clemens von Schacky
Journal:  Vasc Health Risk Manag       Date:  2006

7.  Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.

Authors:  Elliot Offman; Ted Marenco; Sandy Ferber; Judith Johnson; Douglas Kling; Danielle Curcio; Michael Davidson
Journal:  Vasc Health Risk Manag       Date:  2013-10-01

Review 8.  Icosapent ethyl for the treatment of severe hypertriglyceridemia.

Authors:  Hassan Fares; Carl J Lavie; James J DiNicolantonio; James H O'Keefe; Richard V Milani
Journal:  Ther Clin Risk Manag       Date:  2014-06-24       Impact factor: 2.423

9.  A randomized clinical trial to determine the efficacy of manufacturers' recommended doses of omega-3 fatty acids from different sources in facilitating cardiovascular disease risk reduction.

Authors:  Maggie Laidlaw; Carla A Cockerline; William J Rowe
Journal:  Lipids Health Dis       Date:  2014-06-21       Impact factor: 3.876

Review 10.  Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3.

Authors:  Angela Pirillo; Alberico Luigi Catapano
Journal:  Drug Des Devel Ther       Date:  2015-04-10       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.